Want to see CH:YPSN full AI Analyst Report?
Ypsomed Holding AG (YPSN) Stock Price & Analysis
YPSN Stock Chart & Stats
- Day’s Range
- CHF 394.20 - CHF 400.40
- 52-Week Range
- CHF 260.50 - CHF 418.00
- Previous Close
- CHF 395.40
- Volume
- 9,809
- Average Volume (3M)
- 11.56K
- Market Cap
- CHF 5.18B
- Enterprise Value
- CHF 3.97B
- Total Cash (Recent Filing)
- CHF 28.56M
- Total Debt (Recent Filing)
- CHF 260.77M
- Price to Earnings (P/E)
- 24.2
- Beta
- 0.79
- Next Earnings
- Nov 11, 2026 (Est.)
- EPS Estimate
- 5.15
- Last Dividend Ex-Date
- Jul 03, 2026
- Dividend Yield
- 1.11%
Bulls Say, Bears Say
Bulls Say
Delivery Systems Growth And Margin Strength
The core Delivery Systems business is demonstrating strong commercial traction alongside high profitability. Management’s outlook for 12–15% sales growth and EBIT margins above 33% supports durable earnings potential and provides capacity to fund continued expansion.
Record Project Wins And Diversified Pipeline
A large and diversified project pipeline can support future device launches and manufacturing volumes beyond the current reporting period. Record deal activity, broad customer coverage, and a roughly 70% hit rate strengthen visibility into medium-term growth.
Strong Balance Sheet And Expanding Equity
The expanding equity base and moderate recent leverage provide financial resilience as Ypsomed invests in factories and product platforms. This balance-sheet position supports strategic growth while leaving more flexibility to manage execution demands or industry volatility.
Bears Say
Persistently Negative Free Cash Flow
Sustained negative free cash flow indicates that investment and working-capital needs continue to absorb earnings-backed cash generation. Although the deficit improved in 2026, ongoing cash conversion pressure could constrain capital allocation and increase reliance on financing.
Recent Revenue Contraction And Business Exits
The recent top-line decline and planned contract-manufacturing phase-outs create a lower starting revenue base for the next several quarters. Even with limited EBIT impact, the changes may obscure underlying growth and require stronger Delivery Systems expansion to offset lost volume.
Ramp-up And Stranded Costs From Expansion
Large capacity projects can weigh on profitability before new facilities reach efficient utilization. Temporary empty shop floors, site moves, and related ramp-up costs may pressure margins over the coming periods, increasing execution risk despite the company’s long-term expansion plans.
Ypsomed Holding AG News
YPSN FAQ
What was Ypsomed Holding AG’s price range in the past 12 months?
What is Ypsomed Holding AG’s market cap?
When is Ypsomed Holding AG’s upcoming earnings report date?
How were Ypsomed Holding AG’s earnings last quarter?
Is Ypsomed Holding AG overvalued?
Does Ypsomed Holding AG pay dividends?
What is Ypsomed Holding AG’s EPS estimate?
How many shares outstanding does Ypsomed Holding AG have?
What happened to Ypsomed Holding AG’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Ypsomed Holding AG?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Ypsomed Holding AG
Ypsomed Holding AG, together with its subsidiaries, develops, manufactures, and sells injection and infusion systems for safe and simple self-medication companies. The company operates through three segments: Ypsomed Delivery Systems, Ypsomed Diabetes Care, and Others. The Ypsomed Delivery Systems segment provides various injection systems, such as pen injectors, auto-injectors, and wearable injectors, as well as other smart devices. This segment offers its products under the YDS brand. The Ypsomed Diabetes Care segment sells and trades in insulin pumps, infusion sets, pen needles, blood glucose monitoring systems, accessories, and other day-to-day items for diabetics. This segment offers its products under the mylife brand name. The company offers precision turned parts; and contract manufacturing and other services. It markets its products through pharmaceutical partners, as well as through its own distribution network and independent distributors. It operates in Switzerland, Europe, North America, and internationally. Ypsomed Holding AG was founded in 1984 and is headquartered in Burgdorf, Switzerland.
- Sector
- General
- Industry
- Medical - Specialties
- CEO
- Simon Michel
- Employees
- 2,025
- Website
- www.ypsomed.com
- Address
- Brunnmattstrasse 6, Burgdorf, BE, 3401, CH
Ypsomed Holding AG (YPSN) Earnings & Revenues
YPSN Earnings Call
Earnings Call SentimentPositive
The call emphasized strong financial performance, record new project wins, accelerated service capabilities (time‑to‑clinic), and substantial strategic investments (new recyclable platforms and factory capacity). Delivery Systems achieved robust 20% revenue growth and a 33% EBIT margin, free cash generation was strong, and the balance sheet remains healthy (ROCE ~20%, net debt/EBITDA ~0.8). Management acknowledged some one‑off impairments, phased‑out contract manufacturing (modest near‑term revenue reduction), and ramp‑up/stranded costs tied to large capital projects, plus limited tariff and regional competition risks. Overall, positive operational momentum and a clear midterm outlook (CHF 0.9–1.1bn sales and CHF 280–340m EBIT by end of decade) outweigh the manageable near‑term challenges.
View all CH:YPSN earnings summariesYPSN Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 14 | 3 | 5 |
| Technical Analysis | 2 | 3 | 5 |
| Moving Averages | 12 | 0 | 0 |





